To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Floxuridine is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colorectal cancer.
Additional recommended knowledge
Meachanism of action
Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.
Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-fluorouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to Faulding, which became Mayne Pharma.
In the US the drug is supplied by Mayne Pharma as well as APP and Bedford.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Floxuridine". A list of authors is available in Wikipedia.|